The Impact of COVID-19 in Bone Metabolism: Basic and Clinical Aspects
- 13 April 2022
- journal article
- review article
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 54 (08), 540-548
- https://doi.org/10.1055/a-1825-9641
Abstract
The use of standard procedures for the diagnosis of osteoporosis and assessment of fracture risk significantly decreased during the COVID-19 pandemic, while the incidence of fragility fractures was mostly unaltered. Both COVID-19 per se and its treatments are associated with a negative impact on bone health. Preclinical models show that mice infected with SARS-CoV2 even without symptoms display loss of trabecular bone mass two weeks post infection, due to increased numbers of osteoclasts. Osteoporosis medications do not aggravate the clinical course of COVID-19, while preclinical data suggests possible beneficial effects of some therapies. While vitamin D deficiency is clearly associated with a worse clinical course of COVID-19, evidence of improved patient outcome with vitamin D supplementation is lacking. Osteoporosis treatment should not be generally discontinued, and recommendations for substituting therapies are available. Osteoporosis therapies do not interfere with the efficacy or side-effect profiles of COVID-19 vaccines and should not be stopped or indefinitely delayed because of vaccination. Received: 14 March 2022 Accepted after revision: 13 April 2022 Publication Date: 13 April 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyKeywords
This publication has 101 references indexed in Scilit:
- Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsPLOS ONE, 2013
- The Adverse Effects of Estrogen and Selective Estrogen Receptor Modulators on Hemostasis and ThrombosisSeminars in Thrombosis and Hemostasis, 2012
- Advances in Osteoimmunology: Pathophysiologic Concepts and Treatment OpportunitiesInternational Archives of Allergy and Immunology, 2012
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)Journal of Bone and Mineral Research, 2011
- DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytesBlood, 2011
- Effects of Parathyroid Hormone on Immune FunctionJournal of Immunology Research, 2010
- Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 proteinArchiv für die gesamte Virusforschung, 2009
- Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with OsteoporosisJournal of Clinical Endocrinology & Metabolism, 2009
- Lethal Infection of K18- hACE2 Mice Infected with Severe Acute Respiratory Syndrome CoronavirusJournal of Virology, 2007
- Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of RaloxifeneJNCI Journal of the National Cancer Institute, 2004